Business UpdateJun 24, 2026, 08:51 AM
Sanofi's Cenrifki Approved in EU for Secondary Progressive MS
AI Summary
Sanofi announced multiple significant developments, including the European Commission's approval of Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, marking it as the first disability-targeting medicine for this condition. Additionally, the company received approval in Japan for Sarclisa's subcutaneous formulation for multiple myeloma and for Wayrilz to treat immune thrombocytopenia. Sanofi also appointed Paulo Fontoura as the new Global Head of Research & Development Pharma, effective September 1, 2026, bringing extensive experience to the role.
Key Highlights
- Sanofi's Cenrifki (tolebrutinib) approved in EU for secondary progressive multiple sclerosis (SPMS) without relapses.
- Cenrifki is the first disability-targeting medicine for SPMS, based on HERCULES phase 3 study.
- Sarclisa (isatuximab) subcutaneous formulation approved in Japan for multiple myeloma.
- Sarclisa SC approval in Japan based on IRAKLIA phase 3 study, showing non-inferior efficacy to IV formulation.
- Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia.
- Paulo Fontoura appointed as Executive VP, Global Head of R&D Pharma, effective September 1, 2026.
- Fontoura brings over 25 years of experience in academic medicine, translational science, and clinical development.
Price Impact
More from SNY